SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

GOOG is trending as discussions shift towards its AI capabilities and potential market dominance, with some believing it could surpass competitors like NVDA. Community members are analyzing its valuation, debating whether it's overbought, and anticipating further upside. The spotlight is on GOOG's AI advancements and its strategic positioning within the tech landscape.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies around the idea of turning "broke" into an advantage amid market uncertainty, emphasizing resilience and long-term building. Discussions focus on community strength, accumulating during dips, and potential for a significant reversal. The community highlights ongoing development and revenue-generating utilities, aiming for a comeback and a "moon" mission.

shark raptor rocket launcher

SRRL is gaining attention, with community members pointing to its strong chart and steady volume as potential bullish signals. Conversations mention the formation of a "clean range," and some express excitement about a potential breakout. Others urge caution, suspecting pump and dump activity.

Zoom Communications, Inc. engages in the provision of a communications and collaboration platform. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa. The company was founded by Eric S. Yuan in 2011 and is headquartered in San Jose, CA.

Zoom Communications Inc. - Ordinary Shares - Class A

Zoom Video Communications, Inc.

Zoom ($ZM) is trending as traders discuss its Q3 earnings beat and raised guidance, including an additional $1B buyback authorization. Community members are debating the stock's valuation, cash flow, and the impact of AI on its future growth, as well as insiders dumping shares.  Some see it as undervalued and poised for a rally towards $90-$100, while others express skepticism due to competition and limited growth.

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

GRAIL Inc.

GRAL is trending amid discussions about a recent equity distribution agreement and its potential impact on share dilution, with community members weighing the significance of capital raising efforts. Bullish sentiment remains due to the company's game-changing technology and potential for long-term growth in cancer screening, while others express concerns about valuation and competition. Options traders are actively trading calls and puts, reflecting differing perspectives on GRAL's short-term trajectory.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

GOOGL is trending as investors weigh its AI prospects against competitors, particularly after the release of Gemini 3 and news of Meta potentially using Google's TPUs. Community discussions revolve around whether GOOGL can challenge Nvidia's dominance and the stock's valuation amid broader AI hype, with some suggesting it's undervalued while others foresee a correction.

Kaspa was fair-launched in November 2021 with no pre-mine, zero pre-sale, and no coin allocations, and is 100 percent community-managed. Kaspa aims to be the world's global sequencer for traditional finance and decentralized crypto markets by utilizing proof-of-work and its BlockDAG consensus protocol, GHOSTDAG. Being the world's fastest proof-of-work network, Kaspa combines five properties: (1) hard money principles, (2) Bitcoin's ethos of security-first fundamentals (boasting a security threshold of fifty percent with significant market hashrate), (3) decentralization from rapid block rate mining, (4) block speeds faster than any PoW or PoS network, and (5) smart contract development through based-rollups without fragmented liquidity. Ushering in all five properties, Kaspa is on track to fulfill Satoshi Nakamoto's vision of a digital medium of exchange while also advancing global layer-one sequencing and minuscule confirmation times dominated by internet latency (cf. chapter 6 of the the paper for some initial benchmarks). The Kaspa implementation includes a lot of cool features and subprotocols including Reachability to query the DAG's topology, Block data pruning (with near-future plans for block header pruning), SPV proofs, and later subnetwork support which will make future implementation of layer 2 solutions much easier.

Kaspa

Kaspa is trending as the community discusses its potential for future growth, spurred by the approaching launch of smart contracts. Positive sentiment is building about Kaspa's technology and potential listings on major exchanges, although some traders remain skeptical, citing past performance. Discussions also include real-world assets.

Carnival Corp. engages in the operation of cruise ships. It operates through the following business segments: North America and Australia (NAA) Cruise, Europe and Asia (EA) Cruise Operations, Cruise Support, and Tour and Others. The North America and Australia (NAA) Cruise segment includes the Carnival Cruise Line, Holland America Line, Princess Cruises, and Seabourn. The Europe and Asia (EA) Cruise Operations segment consists of AIDA, Costa, Cunard, and P&O Cruises (UK). The Cruise Support segment represents port destinations and private islands for the benefit of its cruise brands. The Tour and Other segment operates hotel and transportation operations of Holland America Princess Alaska Tours. The company was founded in 1972 and is headquartered in Miami, FL.

Carnival Corp. - Ordinary Shares (Paired Stock)

Carnival Corp

CCL is trending due to a sudden drop in cruise line stocks, with community members debating the cause, ranging from concerns about a cautious outlook on the U.S. macroeconomy and capacity growth in the Caribbean to potential manipulation and even geopolitical tensions with Venezuela. Some traders are looking to buy the dip, while others express concerns about the sector's volatility and debt levels. The cruise line sector is down overall, sparking discussions about fair value and market manipulation.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

SMH is trending due to discussions around technical analysis, potential overbought conditions, and analyst ratings adjustments for key holdings like NVDA and AMD. Community members are actively debating whether the ETF is setting up for a correction or has more room to run, while also weighing the impact of potential geopolitical factors and earnings reports.

Aave is a decentralized money market protocol where users can lend and borrow cryptocurrency across 20 different assets as collateral. The protocol has a native token called AAVE, which is also a governance token that lets the community decide the direction of the protocol in a collective manner. Lenders can earn interest by providing liquidity to the market, while borrowers can borrow by collateralizing their cryptoassets to take out loans from the liquidity pools.

AAVE

Aave is trending as community members discuss its potential for growth and recent whale activity, with some suggesting it's undervalued compared to competitors like Compound. The launch of Aave's savings app and integration with traditional finance platforms like Robinhood are also sparking interest. Traders are watching Aave as a leading DeFi protocol, anticipating potential gains amidst regulatory clarity and protocol upgrades.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The company said that AVT03 is approved as a biosimilar to Prolia 60 mg/mL single-use pre-filled syringe and as a biosimilar to Xgeva 70 mg/mL single-use vial.</li><li>STADA will market AVT03 as Kefdensis and Zvogra, while Dr. Reddy’s will market AVT03 as Acvybra and as Xbonzy.&nbsp;</li><li>The EC approval is based on clinical studies that demonstrated equivalent pharmacokinetics and efficacy, and comparable safety and immunogenicity to the reference product, the company said.</li></ul>Alvotech (ALVO) on Monday said that the European Commission (EC) has approved AVT03 as a biosimilar to Amgen’s Prolia and Xgeva, containing the active ingredient denosumab, and used widely to manage osteoporosis.According <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/24/3193283/0/en/Alvotech-Announces-Approval-of-AVT03-a-Biosimilar-to-Prolia-and-Xgeva-denosumab-in-the-European-Economic-Area.html">to</a> Alvotech, the European denosumab market is currently valued at approximately $1.2 billion across all indications. While widely used to manage osteoporosis, it is also used to prevent skeletal-related events in patients with certain cancers. Osteoporosis is a disease in which your bones become weak and are more prone to fracture due to a decrease in bone mineral density and bone mass.<h2 class="st-heading-2">EC Approval</h2>The company said that AVT03 is approved as a biosimilar to Prolia 60 mg/mL single-use pre-filled syringe for the treatment of osteoporosis and bone loss, and as a biosimilar to Xgeva 70 mg/mL single-use vial for the prevention of skeletal-related events in adults with advanced malignancies involving bone.AVT03 will be commercialised in Europe in partnerships with STADA Arzneimittel AG and Dr. Reddy’s, the company said. &nbsp;STADA will market AVT03 as Kefdensis and Zvogra, while Dr. Reddy’s will market AVT03 as Acvybra and as Xbonzy.The EC approval is based on clinical studies that demonstrated equivalent pharmacokinetics and efficacy, and comparable safety and immunogenicity to the reference product, the company said.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Shares of the company traded flat in the pre-market session at the time of writing. On Stocktwits, retail sentiment around ALVO jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/ALVO">ALVO stock</a> is down 61% this year and by 57% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-blockbuster-drug-fails-to-slow-alzheimers-disease-progression-in-studies/cL5bIRrREQT">Novo Nordisk’s Blockbuster Drug Fails To Slow Alzheimer’s Disease Progression In Studies</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, an Alvotech company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Alvotech’s Drug Approved In Europe As Biosimilar For Bone Disease Drug

AVT03 will be commercialised in Europe in partnerships with STADA Arzneimittel AG and Dr. Reddy’s, the company said. 

Equity

AVT03 will be commercialised in Europe in partnerships with STADA Arzneimittel AG and Dr. Reddy’s, the company said. 


Alvotech (NASDAQ:ALVO) Downgraded to Strong Sell Rating by Zacks Research

Zacks Research lowered Alvotech from a "hold" rating to a "strong sell" rating in a report on Thursday...

Alvotech (NASDAQ:ALVO) Downgraded by Wall Street Zen to "Sell"

Wall Street Zen lowered Alvotech from a "hold" rating to a "sell" rating in a research note on Saturday...

Alvotech (NASDAQ:ALVO) Stock Rating Lowered by Wall Street Zen

Wall Street Zen lowered shares of Alvotech from a "hold" rating to a "sell" rating in a report on Saturday...

New Strong Sell Stocks for Nov. 21st

ALVO, AKZOY and ALG have been added to the Zacks Rank #5 (Strong Sell) List on November 21, 2025.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alvotech - ALVO

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alvotech - ALVO INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alvotech - ALVO PR...

ALVO Investigation: Investors Encouraged to Contact Kirby McInerney LLP

The law firm of Kirby McInerney LLP reminds investors its investigation on behalf of Alvotech (Alvotech or the Company) (NASDAQ:ALVO) investors concerning the Companys and/or members of its senior...

UBS Group Has Lowered Expectations for Alvotech (NASDAQ:ALVO) Stock Price

UBS Group cut their price objective on shares of Alvotech from $13.00 to $10.00 and set a "buy" rating for the company in a research report on Tuesday...

Alvotech (NASDAQ:ALVO) Shares Gap Down After Earnings Miss

Alvotech (NASDAQ:ALVO) Shares Gap Down Following Weak Earnings...

Alvotech (NASDAQ:ALVO) Issues Earnings Results, Misses Estimates By $0.10 EPS

Alvotech (NASDAQ:ALVO - Get Free Report) released its quarterly earnings results on Wednesday. The company reported ($0.02) EPS for the quarter, missing the consensus estimate of $0.08 by ($0.10...

Alvotech is a biotechnology company, which engages in the development and manufacture of biosimilar medicines. The firm is focusing on the development of its product candidates. It operates through the following geographical segments: Europe, North America, Asia, and Other. The company was founded by Róbert Vilhelm Wessman in 2013 and is headquartered in Luxembourg.

Alvotech

Buying

Holding

Selling or trimming

Watching from the sidelines

What are you doing with Alphabet ($GOOGL) stock as it hits fresh all-time highs?

Current Price	$5.47
Prev Close	$5.14
Open	$5.15
Dividend Yield	0.00%
50-Day Moving Average	$7.31
Beta	0.56
Avg. Volume	344,339.65
PE Ratio	23.75

52-Week High	$13.70
52-Week Low	$4.70
Market Capitalization	$1.55B
EPS (Annual)	-$0.8654
Price to Book	-9.34
Revenue Per Employee	$474,498.06
Enterprise Value/EBITDA	N/A

ALVO
Alvotech

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ALVO News

ALVOAlvotech